As previously reported, Cowen analyst Tyler Van Buren upgraded Regeneron to Outperform from Market Perform with a price target of $875, up from $775. Recent high-dose Eylea data has "altered the trajectory of Regeneron" and "re-secured" the future of the Eylea franchise, the analyst tells investors in a research note. With the Eylea to high-dose Eylea transition likely to occur rapidly, the impact of biosimilars will be minimal and out-year consensus estimates are "too low," the firm contends. Meanwhile, consensus has Dupixent achieving $15B in global sales by 2027, though Cowen believes this could occur a year or two earlier as it models Dupixent sales surpassing $18B before EU patents expire in 2029. Also, the oncology franchise gets little-to-no value, but Odronextamab and Fianlimab are "real, tangible opportunities," Cowen added.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron upgraded to Outperform from Market Perform at Cowen
- Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization
- Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
- Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent
- Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
